The deal size is 39.6M shares of its common stock and in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3.8M shares of common stock. Leerink, TD Cowen and Evercore ISI acted as joint book running managers for the offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AURA:
- Aura Biosciences Advances CoMpass Phase 3 Trial Progress
- Aura Biosciences announces common stock, pre-funded warrant offering
- Aura Biosciences says Natalie Holles to succeed Elisabet de los Pinos as CEO
- Aura Biosciences price target raised to $15 from $13 at Evercore ISI
- Aura Biosciences: Strong Cash Runway and Accelerating bel-sar Clinical Momentum Support Buy Rating